
    
      Study participants will be vaccinated with one dose of the QIV (split-virion, inactivated) NH
      2013-2014 formulation by the intramuscular route or deep subcutaneous. Immunogenicity will be
      assessed at baseline (Day 0) and 21 days after injection; they will also be followed-up for
      safety for 21 days after injection.
    
  